{"entity":{"id":"richard-carvajal","kind":"person","name":"Richard D. Carvajal","aka":[],"tldr":"Melanoma oncologist who led the tebentafusp programme in the United States and defined targeted therapy for rare melanoma subtypes.","summary":"Richard Carvajal co-led the tebentafusp development programme including the pivotal IMCgp100-202 trial in metastatic uveal melanoma and the early trials of MEK inhibition in uveal melanoma, and led studies of imatinib in KIT-mutant melanoma. He directs medical oncology at Northwell and continues to focus on rare melanoma subtypes.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carvajal%20RD%5BAuthor%5D%20uveal%20melanoma"}],"tags":["uveal-melanoma","rare-cancers"],"related":[],"cancers":["uveal-melanoma","melanoma"],"sections":[],"technologies":["t-cell-engager"],"targets":["gp100","kit"],"drugs":["tebentafusp","imatinib"],"companies":[],"institutions":["northwell-cancer-institute"],"pathways":[],"terms":[],"trials":["imcgp100-202"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Physician-in-Chief and Director of Medical Oncology, Northwell Health Cancer Institute","institutionId":"northwell-cancer-institute","specialisms":["Uveal melanoma","Mucosal and acral melanoma","KIT-mutant melanoma","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carvajal%20RD%5BAuthor%5D%20uveal%20melanoma"}],"papers":[{"title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma (IMCgp100-202)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2103485"},{"title":"KIT as a therapeutic target in metastatic melanoma","journal":"JAMA","year":2011,"doi":"10.1001/jama.2011.746"}],"orcid":"0000-0002-3796-1118"},"route":"/people/richard-carvajal/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"gp100","kind":"target","name":"gp100 (PMEL)","route":"/targets/gp100/"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/"}],"institution":[{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/"}],"trial":[{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/"}]}}